Deazaflavin, also known as 5-deazaflavin, is a synthetic compound with a structure similar to riboflavin, a member of the vitamin B group, though its properties differ significantly. Its synthesis involves replacing the nitrogen at the fifth position of the flavin skeleton with carbon. Flavin compounds, including riboflavin, are organic compounds based on pteridine and derived from isoalloxazine rings.

Deazaflavin is an NAD+ analogue that promotes the production of NAD+ (nicotinamide adenine dinucleotide) in the body, an essential cofactor for cellular health. As people age, NAD+ levels decline, contributing to conditions such as sarcopenia, metabolic diseases, neurodegenerative disorders, and cancer.

Currently, NAD+ precursors like β-nicotinamide mononucleotide (NMN), niacin (NA), niacinamide (NAM), and nicotinamide riboside (NR) are available, with NMN attracting the most market attention.

Deazaflavin shows potential in promoting cell growth, enhancing muscle strength, delaying aging, and improving skin health, making it promising in cosmetics, health products, dietary supplements, and pharmaceuticals. Compared to NMN, deazaflavin offers higher activity, more direct effects, and fewer regulatory restrictions. With the NMN market facing limitations and rising health care demand, deazaflavin may present significant growth opportunities.

Industry analysts note that as an NAD+ analogue, deazaflavin has potential in anti-aging and vitality enhancement, with broad applications in medicine, cosmetics, and health products. The domestic market for deazaflavin is still underdeveloped, offering substantial room for growth. Additionally, with the tightening of NMN regulations and increased market uncertainty, deazaflavin, as a potential NMN alternative, may see new opportunities for development.